Search Results - "Lendrem, Dennis"

Systemic interferon type I and type II signatures in primary Sjögren's syndrome reveal differences in biological disease activity by Bodewes, Iris L A, Al-Ali, Shereen, van Helden-Meeuwsen, Cornelia G, Maria, Naomi I, Tarn, Jessica, Lendrem, Dennis W, Schreurs, Marco W J, Steenwijk, Eline C, van Daele, Paul L A, Both, Tim, Bowman, Simon J, Griffiths, Bridget, Ng, Wan-Fai, Versnel, Marjan A

“…Abstract Objective To assess the relationships between systemic IFN type I (IFN-I) and II (IFN-II) activity and disease manifestations in primary SS (pSS)…”
Get full text

Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study by Baker, Kenneth F., Skelton, Andrew J., Lendrem, Dennis W., Scadeng, Adam, Thompson, Ben, Pratt, Arthur G., Isaacs, John D.

“…Many patients with rheumatoid arthritis (RA) achieve disease remission with modern treatment strategies. However, having achieved this state, there are no…”
Get full text

Coping strategies, illness perceptions, and relationship dynamics contribute to female sexual function and sexual distress in Sjögren's syndrome by McCready, Jemma L, Deary, Vincent, Collins, Tracy L, Lendrem, Dennis W, Hackett, Katie L

“…Sexual dysfunction and sexual distress are common complaints for women with the autoimmune rheumatic disease Sjögren's syndrome (SS); however, the role of…”
Get full text

Gain‐of‐function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC) by Zheng, Jie, Veerdonk, Frank L., Crossland, Katherine L., Smeekens, Sanne P., Chan, Chun M., Al Shehri, Tariq, Abinun, Mario, Gennery, Andrew R., Mann, Jelena, Lendrem, Dennis W., Netea, Mihai G., Rowan, Andrew D., Lilic, Desa

“…Signal transducer and activator of transcription 3 (STAT3) triggered production of Th‐17 cytokines mediates protective immunity against fungi. Mutations…”
Get full text

Why is it hard to terminate failing projects in pharmaceutical R&D? by Peck, Richard W., Lendrem, Dennis W., Grant, Iain, Lendrem, B. Clare, Isaacs, John D.

“…'Quick-kill' strategies in pharmaceutical research and development aim to reduce late-stage attrition by bringing project termination decisions forward, to an…”
Get full text

Micro-RNA content of circulating extracellular vesicles in early rheumatoid arthritis as biomarkers and mediators of methotrexate efficacy by Maunder, Daniel, Brown, Philip M, Barron-Millar, Ben, Lendrem, Dennis W, Naamane, Najib, Macdonald, Jamie, Wang, Xiao N, Isaacs, John D, Anderson, Amy E, Morgan, Ann W, Crossland, Rachel E, Mackie, Sarah L, Pratt, Arthur G

“…Extracellular vesicles (EVs) are abundant in body fluids, contributing to intercellular signalling by transferring cargo that includes microRNAs…”
Get full text

Routine musculoskeletal ultrasound findings impact diagnostic decisions maximally in autoantibody-seronegative early arthritis patients by Iqbal, Kundan, Lendrem, Dennis W, Hargreaves, Ben, Isaacs, John D, Thompson, Ben, Pratt, Arthur G

“…Abstract Objective The diagnostic value added by musculoskeletal ultrasound (MSUS) over standard clinical and laboratory parameters has proved difficult to…”
Get full text

Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome by Traianos, Emmanuella Young, Locke, James, Lendrem, Dennis, Bowman, Simon, Hargreaves, Ben, Macrae, Victoria, Tarn, Jessica Rachael, Ng, Wan-Fai

“…Primary Sjögren’s syndrome (pSS) is an autoimmune disease characterised by an increased risk for non-Hodgkin lymphoma (NHL) development. Ectopic germinal…”
Get full text

Comorbidities in the UK Primary Sjögren's Syndrome Registry by Tarn, Jessica, Lendrem, Dennis, Barnes, Michael, Casement, John, Ng, Wan-Fai

“…Primary Sjögren's Syndrome (PSS) is a chronic disease characterised by symptoms of oral and ocular dryness, pain, fatigue, anxiety and depression. PSS patients…”
Get full text

CD4+ and B Lymphocyte Expression Quantitative Traits at Rheumatoid Arthritis Risk Loci in Patients With Untreated Early Arthritis: Implications for Causal Gene Identification by Thalayasingam, Nishanthi, Nair, Nisha, Skelton, Andrew J, Massey, Jonathan, Anderson, Amy E, Clark, Alexander D, Diboll, Julie, Lendrem, Dennis W, Reynard, Louise N, Cordell, Heather J, Eyre, Stephen, Isaacs, John D, Barton, Anne, Pratt, Arthur G

“…Rheumatoid arthritis (RA) is a genetically complex disease of immune dysregulation. This study sought to gain further insight into the genetic risk mechanisms…”
Get full text

The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy by Cooles, Faye A.H., Anderson, Amy E., Lendrem, Dennis W., Norris, Julie, Pratt, Arthur G., Hilkens, Catharien M.U., Isaacs, John D.

“…At diagnosis (baseline), most patients received a depot intramuscular glucocorticoid injection, but to reduce confounding,2 we excluded from longitudinal IGS…”
Get full text

Erratum to "Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study" [J. Autoimmun. 105 (December 2019) 102298] by Baker, Kenneth F, Skelton, Andrew J, Lendrem, Dennis W, Scadeng, Adam, Thompson, Ben, Pratt, Arthur G, Isaacs, John D

Get full text

Schrödinger’s pipeline and the outsourcing of pharmaceutical innovation by McMeekin, Peter, Lendrem, Dennis W., Lendrem, B. Clare, Pratt, Arthur G., Peck, Richard, Isaacs, John D., Jones, David

“…•The Global Financial Crisis (2007–2008) shifted the worldwide markets.•This permitted Big Pharma to experiment with new R&D models for open innovation.•Ten…”
Get full text

Revisiting the JOQUER trial: stratification of primary Sjögren’s syndrome and the clinical and interferon response to hydroxychloroquine by Collins, Alexis, Lendrem, Dennis, Wason, James, Tarn, Jessica, Howard-Tripp, Nadia, Bodewes, Iris, Versnel, Marjan A., Gottenberg, Jacques-Eric, Seror, Raphaele, Mariette, Xavier, Ng, Wan-Fai

“…To re-analyse the clinical outcomes and interferon (IFN) activity data from the JOQUER trial, a phase III trial investigating hydroxychloroquine (HCQ) in…”
Get full text

Expression of STAT3-regulated genes in circulating CD4+ T cells discriminates rheumatoid arthritis independently of clinical parameters in early arthritis by Anderson, Amy E, Maney, Nicola J, Nair, Nisha, Lendrem, Dennis W, Skelton, Andrew J, Diboll, Julie, Brown, Philip M, Smith, Graham R, Carmody, Ruaidhrí J, Barton, Anne, Isaacs, John D, Pratt, Arthur G

“…Abstract Objectives Dysregulated signal transduction and activator of transcription-3 (STAT3) signalling in CD4+ T cells has been proposed as an early…”
Get full text

COVID-19 Management in a UK NHS Foundation Trust with a High Consequence Infectious Diseases Centre: A Retrospective Analysis by Baker, Kenneth F, Hanrath, Aidan T, Schim van der Loeff, Ina, Tee, Su Ann, Capstick, Richard, Marchitelli, Gabriella, Li, Ang, Barr, Andrew, Eid, Alsafi, Ahmed, Sajeel, Bajwa, Dalvir, Mohammed, Omer, Alderson, Neil, Lendrem, Clare, Lendrem, Dennis W, Covid-Control Group, Covid-Clinical Group, Pareja-Cebrian, Lucia, Welch, Andrew, Field, Joanne, Payne, Brendan A I, Taha, Yusri, Price, David A, Gibbins, Christopher, Schmid, Matthias L, Hunter, Ewan, Duncan, Christopher J A

“…Recent large national and international cohorts describe the baseline characteristics and outcome of hospitalised patients with COVID-19, however there is…”
Get full text

Lost in space: design of experiments and scientific exploration in a Hogarth Universe by Lendrem, Dennis W., Lendrem, B. Clare, Woods, David, Rowland-Jones, Ruth, Burke, Matthew, Chatfield, Marion, Isaacs, John D., Owen, Martin R.

“…•R&D technical problems give rise to complex, or Hogarth, problem spaces.•Traditional methods of exploring such spaces are flawed.•Design of experiments tools…”
Get full text

Adenosine metabolic signature in circulating CD4+ T cells predicts remission in rheumatoid arthritis by Brown, Philip M, Anderson, Amy E, Naamane, Najib, Lendrem, Dennis W, Morgan, Ann W, Isaacs, John D, Pratt, Arthur G

“…ObjectivesLong-term outcomes in rheumatoid arthritis (RA) depend on early and effective disease control. Methotrexate (MTX) remains the first-line disease…”
Get full text

Robust optimization of SWATH-MS workflow for human blood serum proteome analysis using a quality by design approach by Serrano-Blesa, Edith, Porter, Andrew, Lendrem, Dennis W, Pitzalis, Costantino, Barton, Anne, Treumann, Achim, Isaacs, John D

“…Abstract Background It is not enough to optimize proteomics assays. It is critical those assays are robust to operating conditions. Without robust assays,…”
Get full text

The development speed paradox: can increasing development speed reduce R&D productivity? by Lendrem, Dennis W., Lendrem, B. Clare

“…•Shifting tasks into parallel, reduces cycle time and increases development speed.•Increasing development speed reduces time to market for successful…”
Get full text